Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Scheltens, P. et al. Alzheimer’s disease. Lancet 397, 1577–1590 (2021).
2. Zhang, Y. et al. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future. Signal Transduct. Target Ther. 8, 248 (2023).
3. van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388, 9–21 (2023).
4. Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512–527 (2023).
5. Usman, M. B. et al. Immunotherapy for Alzheimer’s disease: current scenario and future perspectives. J. Prev. Alzheimers Dis. 8, 534–551 (2021).